Guardant Health, Inc.
GH
#1058
Rank
$22.937 B
Marketcap
United States
Country
$170.92
Share price
3.53%
Change (1 day)
209.55%
Change (1 year)
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect…
Key Metrics
Trailing P/E
—
Forward P/E
-446.31
EPS (TTM)
$-3.52
Forward EPS
$-0.40
Price / Book
—
EV / EBITDA
-58.6x
Beta
1.58
Dividend Yield
—
Return on Equity
—
Return on Assets
-18.07%
Debt / Equity
—
Current Ratio
4.03
Gross Margin
65.01%
Operating Margin
-38.25%
Net Profit Margin
-38.33%
Free Cash Flow
$26.607M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
+8.76%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$982.021M
Latest Net Income$-416,277,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Guardant Health, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
GH
No recent news available. Set FINNHUB_API_KEY to enable news.
